Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

DISEASE CHARACTERISTICS: * Histologically confirmed glioblastoma multiforme * Focal disease * Progressive or recurrent disease after prior treatment with radiotherapy and/or chemotherapy * Low-grade astrocytoma that progressed to glioblastoma multiforme after prior radiotherapy and/or chemotherapy allowed * Gross tumor volume 5-60 mL * No intraventricular tumor, infratentorial tumor, or tumor that communicates with the ventricles * No bilateral non-contiguous gadolinium-enhancing tumor * No diffuse disease, defined as any satellite lesion \> 1.5 cm from the anticipated location of a catheter tip OR \> 2 satellite lesions * No ventricular invasion outside the anticipated radiotherapy volume PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL Hepatic * Bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Hepatitis B negative * No evidence of active hepatitis Renal * Creatinine ≤ 1.7 mg/dL * BUN ≤ 2 times ULN Cardiovascular * No uncontrolled hypertension * No unstable angina pectoris * No uncontrolled cardiac dysrhythmia Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to undergo MRI * Mini Mental State Exam score ≥ 15 * No serious infection * No other medical illness that would preclude study participation * No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer * No psychological or sociological condition, addictive disorder, or other condition that would preclude study compliance * No known or suspected allergy to study drug or iodine * No known HIV positivity PRIOR CONCURRENT THERAPY: Biologic therapy * No prior monoclonal antibodies * No prior local immunotherapy or treatment with the following biologic agents: * Immunotoxins * Immunoconjugates * Antiangiogenesis compounds * Antisense agents * Peptide receptor antagonist * Interferons * Interleukins * Tumor infiltrating lymphocytes * Lymphokine-activated killer cells * Gene therapy Chemotherapy * See Disease Characteristics * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) * At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer\^® ) Endocrine therapy * Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks before study entry Radiotherapy * See Disease Characteristics * At least 3 months since prior radiotherapy * No prior brachytherapy or radiosurgery Surgery * At least 4 weeks since prior surgery Other * Recovered from all prior therapy * At least 1 month since prior investigational agents * No more than 2 prior treatment regimens * No other prior local therapy